Apoptosis-Inducing Effect of Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF-??B in BxPC-3 Pancreatic Cancer Cell Line
- 1 May 2004
- journal article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 28 (4) , e90-e95
- https://doi.org/10.1097/00006676-200405000-00020
Abstract
Cancer chemotherapeutic strategies should be devised to provide higher tumor response and lower toxicity for combination chemotherapy. Genistein has been shown to inhibit the growth of various cancer cells in vitro and in vivo without toxicity to normal cells. The antitumor effects of genistein could be in part due to inactivation of NF-κB activity. In contrast, chemotherapeutic agents inadvertently induce NF-κB activity, which may lead to chemoresistance. In this study, we investigated whether the inactivation of NF-κB by genistein would enhance the efficacy of chemotherapeutic agents. BxPC-3 pancreatic cancer cells were pretreated with 30 μmol/L genistein for 24 hours and then exposed to lower concentrations of chemotherapeutic agents for an additional 24 hours. Cell growth inhibition assay, apoptosis assay, and NF-κB EMSA were performed. The combination of 30 μmol/L genistein with 1 nmol/L docetaxel or 100 nmol/L cisplatin elicited significantly greater inhibition of cell growth compared with either agent alone. The combination treatment induced more apoptosis in BxPC-3 cells compared with single agents. Moreover, the NF-κB activity was significantly increased within 2 hours of docetaxel or cisplatin treatment, and the NF-κB–inducing activity of these agents was completely abrogated in cells pretreated with genistein. These results clearly suggest that genistein pretreatment, which inactivates NF-κB activity, together with other cellular effects of genistein, may contribute to increased cell growth inhibition and apoptosis inducing effects of nontoxic doses of docetaxel and cisplatin, which could be a novel strategy for the treatment of pancreatic cancer.Keywords
This publication has 26 references indexed in Scilit:
- Phase II Study of Gemcitabine, Cisplatin, and Infusional Fluorouracil in Advanced Pancreatic CancerJournal of Clinical Oncology, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Gemcitabine-based therapy in pancreas cancerCancer, 2002
- A Phase I Study of Weekly Gemcitabine and Docetaxel in Patients with Advanced Cancer: A Hoosier Oncology Group StudyOncology, 2002
- Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cellsBiochemical Pharmacology, 2002
- Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy.Cancer Investigation, 2002
- NF-κB Activation Mediates Doxorubicin-induced Cell Death in N-type Neuroblastoma CellsPublished by Elsevier ,2001
- Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinomaCancer, 2001
- A phase I–II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)Annals of Oncology, 1999
- A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancerBritish Journal of Cancer, 1996